CalciMedica is trading at $1.12, up 5.16%, amid biotech-sector strength. - CalciMedica closed regular trading at $1.06 on October 20; the after-hours quote is a further gain. - No verified fresh company-specific announcement was identified for October 20. FDA-alignment news for Auxora’s pancreatitis trial was announced in July and is not a confirmed new catalyst. - XBI rose 3.64% on October 20, and the supplied news context describes CalciMedica’s move as in line with sector strength.